NUP85: A Potential Drug Target and Biomarker (G79902)

Target Name: NUP85

NCBI ID: G79902

NUP85

NUP85: A Potential Drug Target and Biomarker

Nucleoporin 85kDa (NUP85) is a protein that is expressed in various cell types, including neurons, glial cells, and blood vessels. It is a member of the nucleoporin family, which is a family of transmembrane proteins that play a crucial role in regulating the passage of nucleotides into and out of cells. NUP85 is expressed in high levels in the brain, and its expression has been linked to various neurological and psychiatric disorders. As a result, NUP85 has emerged as a promising drug target and biomarker for a variety of neurological conditions.

The NUP85 gene was identified in the human genome using DNA sequencing technology. The gene is located on chromosome 16 and encodes a protein of 85 kilodalton (kDa) protein. The protein is composed of 214 amino acid residues and has a calculated pI of 11.9. NUP85 is predominantly expressed in the brain, with high levels also being observed in the heart, liver, and pancreas.

NUP85 is involved in the regulation of nucleotide transport into and out of cells. In addition to its role in regulating the passage of nucleotides into the cell, NUP85 is also involved in the regulation of the release of nucleotides from the cell. This is accomplished through its interaction with various co-factors, including the protein TRPV4.

NUP85 has been linked to a number of neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. In addition to its involvement in these disorders, NUP85 is also implicated in the development and progression of various types of cancer. This is because NUP85 has been shown to promote the growth and survival of cancer cells, and it is also expressed in the blood vessels that supply cancer cells with the oxygen and nutrients they need to grow.

One of the potential benefits of targeting NUP85 as a drug target is that it is located in the brain and has been shown to be involved in the development and progression of various neurological disorders. This means that targeting NUP85 with drugs that can modulate its activity could potentially lead to a more effective treatment of these disorders. Additionally, because NUP85 is also expressed in other tissues and cells, targeting it as a drug target has the potential to be a more effective and less invasive approach to treating these disorders than other current treatments.

Another potential benefit of targeting NUP85 as a drug target is that it is a protein that is expressed in high levels in the brain, making it a potentially more effective target for drugs that can modulate its activity. This is because drugs that can bind to NUP85 and modulate its activity are likely to have a more targeted and effective effect on the brain, rather than having a more diffuse and widespread effect on the body.

In addition to its potential as a drug target, NUP85 has also been identified as a potential biomarker for a variety of neurological disorders. This is because its expression is associated with the development and progression of these disorders, and drugs that can modulate NUP85 activity may be able to provide diagnostic information about the presence and progression of these disorders. For example, NUP85 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and levels of NUP85 have been linked to the severity of this disease. Similarly, NUP85 has been shown to be expressed in the brains of individuals with Parkinson's disease, and levels of NUP85 have been linked to the severity of this disease.

In conclusion, NUP85 is a protein that is involved in the regulation of nucleotide transport into and out of cells, and it is expressed in high levels in the brain. Its expression is associated with the development and progression of various neurological and psychiatric disorders, and it has been shown to promote the growth and survival of cancer cells. As a result, NUP85 is a promising drug target and biomarker for a variety of neurological conditions. Further research is needed to fully understand the role of NUP85 in these disorders and to develop effective treatments.

Protein Name: Nucleoporin 85

Functions: Essential component of the nuclear pore complex (NPC) that seems to be required for NPC assembly and maintenance (PubMed:12718872). As part of the NPC Nup107-160 subcomplex plays a role in RNA export and in tethering NUP96/Nup98 and NUP153 to the nucleus (PubMed:12718872). The Nup107-160 complex seems to be required for spindle assembly during mitosis (PubMed:16807356). NUP85 is required for membrane clustering of CCL2-activated CCR2 (PubMed:15995708). Seems to be involved in CCR2-mediated chemotaxis of monocytes and may link activated CCR2 to the phosphatidyl-inositol 3-kinase-Rac-lammellipodium protrusion cascade (PubMed:15995708). Involved in nephrogenesis (PubMed:30179222)

The "NUP85 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NUP85 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets